Cart
sales@molnova.com
Fumagillol
CAS No. 108102-51-8
Fumagillol( —— )
Catalog No. M23289 CAS No. 108102-51-8
Fumagillol is a direct precursor of the potent angiogenesis inhibitors TNP-470 and fumagillin.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 76 | In Stock |
|
| 5MG | 69 | In Stock |
|
| 10MG | 117 | In Stock |
|
| 25MG | 215 | In Stock |
|
| 50MG | 318 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFumagillol
-
NoteResearch use only, not for human use.
-
Brief DescriptionFumagillol is a direct precursor of the potent angiogenesis inhibitors TNP-470 and fumagillin.
-
DescriptionFumagillol is a direct precursor of the potent angiogenesis inhibitors TNP-470 and fumagillin.
-
In VitroFumagillol derivatives have no significant cytotoxic effect on CHO cells.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number108102-51-8
-
Formula Weight282.38
-
Molecular FormulaC16H26O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (354.13 mM)
-
SMILESC[C@]1(C(C(C(CC2)O)OC)C22OC2)OC1CC=C(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00582-20. Janak Padia, Liudmila Kulakova, et al.Discovery and Preclinical Development of Antigiardiasis Fumagillol Derivatives.
molnova catalog
related products
-
Pelargonidin3-O-[6-O...
Pelargonidin3-O-[6-O-(E)-P-coumarin-2-O-β-D-glucoside}-β-D-glucoside]-5-O-(6-O-malonyl）-β-D-glucoside
-
PiB
PiB is a standard for analysis of 11C-PiB. 11C-PiB is a β-amyloid PET imaging tracer for Alzheimer's disease diagnosis.
-
4-Amino-5-Bromopyrro...
4-Amino-5-Bromopyrrolo[2,3-D]Pyrimidine is a marine derived natural products found in Echinodictyum sp.
